Back to Search
Start Over
Correction to: Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer.
- Source :
-
Clinical Drug Investigation . Jan2019, Vol. 39 Issue 1, p113-113. 1p. - Publication Year :
- 2019
-
Abstract
- Dr. Arteaga serves on an Advisory Board for Novartis and was a consultant for AstraZeneca from 2015 to 2016. All other authors declare that they have no competing interests. [ABSTRACT FROM AUTHOR]
- Subjects :
- *METASTATIC breast cancer
*HER2 protein
Subjects
Details
- Language :
- English
- ISSN :
- 11732563
- Volume :
- 39
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Clinical Drug Investigation
- Publication Type :
- Academic Journal
- Accession number :
- 134562638
- Full Text :
- https://doi.org/10.1007/s40261-019-00748-x